Product Program year 2024 Source: CMS Open Payments

Feraheme

Drug For the treatment of iron deficiency anemia associated with chronic kidney disease

NDC 59338-775-01

Open in the dashboard

General payments

$416,159

3,141 payments

Research payments

$1,003,820

200 payments

Through program year 2024, $416,159 in general payments and $1,003,820 in research payments were reported against Feraheme (For the treatment of iron deficiency anemia associated with chronic kidney disease).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

9 rows
Year Kind Amount Payments
2024 General $48,927 8
2024 Research $146,962 48
2023 General $78,324 15
2023 Research $286,265 50
2022 General $72,801 863
2022 Research $294,084 49
2021 General $216,107 2,255
2021 Research $270,509 52
2020 Research $6,000 1

Breakdown

Who paid General payments · program years 2021–2024
  1. AMAG Pharmaceuticals, Inc. $416,159 3,141 payments
Top recipients General payments · program year 2024
  1. Csanad Varallyay Diagnostic Radiology · Portland, OR $48,927 100% · 8 payments

Each share is of general payments naming this product in 2024.

Specialties paid General payments · program year 2024
  1. Diagnostic Radiology Radiology $48,927 100% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2024
  1. Oregon $48,927 100% · 1 recipient

Each share is of general payments naming this product in 2024 where a state was reported.

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to FERAHEME
Billing code Providers Services Paid by Medicare
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) Q0138 977 26,842,035 $7,312,080

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

3,141 general · 200 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record